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Cortisol overproduction results 
from DNA methylation of CYP11B1 
in hypercortisolemia
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Adrenocortical hormone excess, due to primary aldosteronism (PA) or hypercortisolemia, causes 
hypertension and cardiovascular complications. In PA, hypomethylation of aldosterone synthase 
(CYP11B2) is associated with aldosterone overproduction. However, in hypercortisolemia, the role 
of DNA methylation of 11β-hydroxylase (CYP11B1), which catalyzes cortisol biosynthesis and is 
highly homologous to CYP11B2, is unclear. The aims of our study were to determine whether the 
CYP11B1 expression was regulated through DNA methylation in hypercortisolemia with cortisol-
producing adenoma (CPA), and to investigate a possible relationship between DNA methylation and 
somatic mutations identified in CPA. Methylation analysis showed that the CYP11B1 promoter was 
significantly less methylated in CPA than in adjacent unaffected adrenal tissue and white blood cells. 
Furthermore, in CPA with somatic mutations in either the catalytic subunit of protein kinase A (PRKACA) 
or the guanine nucleotide-binding protein subunit alpha (GNAS) gene, the CYP11B1 promoter was 
significantly hypomethylated. In addition, DNA methylation reduced CYP11B1 promoter activity using 
a reporter assay. Our study results suggest that DNA methylation at the CYP11B1 promoter plays a role 
in the regulation of CYP11B1 expression and cortisol production in CPA, and that somatic mutations 
associated with CPA reduce DNA methylation at the CYP11B1 promoter.
Hypercortisolemia is a hormonal disorder caused by the prolonged exposure of the body to high levels of cortisol. 
Cortisol excess in hypercortisolemia is associated with substantial morbidity and mortality. Metabolic disorders 
such as hypertension, diabetes mellitus, and hyperlipidemia are common among hypercortisolemia patients and 
contribute to increased cardiovascular complications1. Endogenous hypercortisolemia results from a variety of 
diseases and disorders, including cortisol-producing adenoma (CPA), adrenal carcinoma, primary pigmented 
nodular adrenocortical disease (PPNAD), bilateral adrenal hyperplasia (BAH), adrenocorticotropic hormone 
(ACTH)-independent macronodular adrenocortical hyperplasia (AIMAH), excess ACTH produced by the pitu-
itary (Cushing’s disease) or by ectopic tumors producing ACTH (ectopic Cushing’s syndrome)2.
Cortisol biosynthesis is mainly regulated by the cyclic AMP (cAMP)/protein kinase A (PKA) signaling 
pathway activated by ACTH secreted from the anterior pituitary gland3. In this pathway, 11β-hydroxylase 
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(cytochrome P450 family 11 subfamily B member 1: CYP11B1) catalyzes the final step of cortisol biosynthesis. 
Recently, exome sequencing revealed that CPAs frequently carry somatic mutations in the catalytic subunit of 
PKA (PRKACA) that leads to the activation of cAMP response element-binding protein (CREB), and the guanine 
nucleotide-binding protein subunit alpha (GNAS) gene, resulting in an activation of PKA4, 5. Both mutations 
result in increase of CYP11B1 expression and thereby an excessive production of cortisol. However, the molecular 
mechanism how these mutations affect CYP11B1 expression has not been well clarified.
DNA methylation is a fundamental epigenetic mechanism that regulates gene expression6. Generally, gene 
transcription is active at unmethylated DNA regions, and DNA methylation results in reduced gene expression. 
Recent studies demonstrated that aldosterone synthase (cytochrome P450 family 11 subfamily B member 2: 
CYP11B2) in aldosterone-producing adenomas (APA) is upregulated by DNA hypomethylation of its promoter 
region7–9. Aldosterone is secreted by zona glomerulosa, the outermost layer in the adrenal cortex, and cortisol 
is secreted by zona fasciculata, which is situated between the glomerulosa and reticularis. In addition, CYP11B2 
shows high homology to the CYP11B1, and both are located on chromosome 8 (8q24.3)10. However, the rela-
tionship between CYP11B1 overexpression and DNA methylation in hypercortisolemia has yet to be elucidated. 
Therefore, it is intriguing to focus on CPA that overexpresses CYP11B111, 12.
In this study, to clarify the molecular mechanism of cortisol production in hypercortisolemia, we examined 
whether the CYP11B1 expression in CPA was regulated through DNA methylation by carrying out multiple 
experiments.
Results
CYP11B1 expression in cortisol-producing adenomas. Immunohistochemical analysis revealed that 
all CPAs showed positive staining for CYP11B1 while staining negative for aldosterone synthase, CYP11B2 (Fig. 1, 
Figure S1). Patient 10 had two adenomas with different staining patterns (Figure S2), the adenoma with stronger 
staining for CYP11B1 was defined as the culprit lesion and used in the following experiments. We next compared 
the expression level of CYP11B1 between CPA and adjacent unaffected adrenal tissue (AUAT), and found that 
CPA expresses CYP11B1 at higher level than AUAT (Figure S3). In addition, we performed Western blot analysis 
and confirmed that CYP11B1 protein level was significantly higher in CPA than in AUAT (Figure S4).
Prevalence of PRKACA or GNAS gene mutations in cortisol-producing adenomas. Eight of the 
13 CPA patients had somatic mutations in either the PRKACA or the GNAS gene (Table 1, Table S1, Figure S5). 
Two patients had the p.L206R mutation of the PRKACA gene. Among six patients with GNAS gene mutations, 
three CPAs had p.R201H. The other three patients carried p.R201C, p.R201S, and p.Q227R mutations respec-
tively. None of the patients had somatic mutations in catenin beta-1 (CTNNB1) gene. There was no significant 
difference in the clinical characteristics of patients with and without mutations (Table 1).
CpG sites and transcription factor-binding sites of the CYP11B1 promoter in cortisol-producing 
adenoma. The CpG site is a DNA region where a cytosine nucleotide occurs next to a guanine nucleotide 
in the linear sequence of genome DNA, and is a target for DNA methylation. DNA methylation occurs almost 
exclusively at cytosine of CpG site. When we manually searched for CpG sites in the CYP11B1 promoter region, 
we found five CpG sites, and all of them are present near transcription factor-binding sites (Fig. 2a, Figure S6).
Figure 1. Confirmation of CYP11B1 overexpression in cortisol-producing adenomas. The 
immunohistochemical analysis of case #1 is shown as representative of all 13 cases. Formalin-fixed paraffin-
embedded tissue sections were stained with Hematoxylin & Eosin (HE), anti-CYP11B1, and anti-CYP11B2 
antibodies. CPA, cortisol-producing adenoma; AUAT, adjacent unaffected adrenal tissue.
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Methylation status of the CYP11B1 promoter in cortisol-producing adenoma. To examine the 
role of DNA methylation on high CYP11B1 expression in CPA, we compared the DNA methylation level of five 
CpG sites in the CYP11B1 promoter (Fig. 2a, Figure S6) in CPA with the same sites in AUAT, white blood cells 
(WBC), zona fasciculata (ZF) of normal adrenal cortex, non-functioning adrenal tumor (NFT) and H295R cells. 
The methylation of all five sites in CPA was significantly lower than in AUAT, WBC, ZF, NFT and H295R cells 
(Fig. 2b). Furthermore, methylation status was also significantly lower in AUAT, ZF and NFT, compared to WBC 
and H295R cells. Additionally, CPAs that carried somatic mutations (n = 8) were significantly less methylated in 
the five CpG sites of the CYP11B1 promoter compared to those without mutations (n = 5) (Fig. 3a).
All patients
CPA with PRKACA 
or GNAS mutation
CPA without PRKACA 
or GNAS mutation
Number of cases, n 13 8 5
Age, y [mean (range)] 53 (33–65) 52 (37–64) 53 (33−65)
Sex, males/females 4/9 2/6 2/3
Body mass index, kg/m2 24 ± 4 24 ± 2 25 ± 6
Systolic blood pressure, mmHg 146 ± 25 150 ± 9 139 ± 2
Diastolic blood pressure, mmHg 90 ± 15 93 ± 6 85 ± 3
Serum potassium, mEq/L 3.8 ± 0.3 3.7 ± 0.1 3.8 ± 0.2
Baseline F, nmol/L 362 ± 31 373 ± 41 343 ± 50
24 h urinary F, µg/day 58 ± 10† 64 ± 15‡ 46 ± 8§
Midnight F, nmol/L 268 ± 50† 255 ± 61‡ 290 ± 98§
F after 1 mg DST, nmol/L 241 ± 51 249 ± 55 227 ± 110
Adrenal tumor size, mm 26 ± 2 23 ± 2 30 ± 4
Table 1. Summary of clinical characteristics of patients with cortisol-producing adenomas in this study. 
†n = 11, ‡n = 7, §n = 4. Data presented as mean ± SEM, except where noted otherwise. F, serum cortisol 
concentration; DST, dexamethasone suppression test.
Figure 2. Hypomethylation of the CYP11B1 promoter in cortisol-producing adenomas. (a) CpG sites and 
transcription factor-binding sites in the human CYP11B1 promoter. Nucleotide numbers are relative to the 
transcription start site. CpG sites around the transcription factor-binding sites are denoted as lollipops and 
numbered. b, Comparison of methylation levels of the CYP11B1 promoter among cortisol-producing adenomas 
(CPA) (n = 13), adjacent unaffected adrenal tissue (AUAT) (n = 13), white blood cells (WBC) (n = 13), zona 
fasciculata (ZF) of normal adrenal cortex (n = 7), non-functioning adrenal tumor (NFT) (n = 7), and H295R 
cells (H295R) (n = 13). Methylation levels at five CpG sites were measured by pyrosequencing. Data are 
shown as the mean ± SEM, and analyzed with the Mann-Whitney U test between each two groups. *P < 0.05, 
**P < 0.01.
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Mutations in both PRKACA and GNAS facilitate phosphorylation of the transcription factor CREB5, which 
then binds to the Ad1/ cAMP response element (CRE) site in the CYP11B1 promoter. Therefore, we focused our 
analysis on the two CpG sites (CpG#1 and CpG#2 in Fig. 2a) near the Ad1/CRE site. In CPA, the somatic muta-
tions reduced the methylation level of these two CpG sites significantly, while the methylation level of the other 
three CpG sites were not affected by somatic mutations (Fig. 3b).
CYP11B1 promoter activity is regulated by DNA methylation. We examined the CYP11B1 pro-
moter activity using a luciferase assay. We isolated the CYP11B1 promoter region (−302/+7) that contains five 
CpG sites around three transcription factor-binding sites: Ad4/steroidogenic factor (SF)−1, Ad5, and Ad1/CRE 
(Fig. 2a). The CYP11B1 promoter showed significant activity (Fig. 4a) when a reporter plasmid carrying this pro-
moter region was transfected into human adrenocortical carcinoma H295R cells.
To evaluate the effect of DNA methylation on CYP11B1 promoter activity, the reporter plasmid was methyl-
ated in vitro by the CpG-specific methyltransferase M.SssI. The methylation level was confirmed by digestion with 
the methylation-sensitive restriction enzyme BsiEI (Fig. 4b). When the methylated plasmids were transfected into 
H295R cells, the promoter activity was reduced proportionally with the increase in DNA methylation (Fig. 4c, 
Figure S7).
DNA hypomethylation around the Ad1/CRE site is induced by cyclic AMP stimulation. Since 
mutations in both PRKACA and GNAS genes lead to the constitutive activation of the PKA pathway, we examined 
the effect of cAMP-induced PKA activation on DNA methylation using a cAMP analog, 2′-O-dibutyladenosine 
3′, 5′-cyclic monophosphate (dibutyric cAMP; dbcAMP). When we treated H295R cells with dbcAMP, the level 
of CYP11B1 mRNA significantly increased (Fig. 5a). Furthermore, dbcAMP stimulation significantly reduced 
DNA methylation at only the two CpG sites around the Ad1/CRE site (Fig. 5b, lower panel). We did not observe 
significant reduction in methylation levels in the other CpG sites (Fig. 5b, upper panel, Figure S8).
Discussion
In the present study, we found that the CYP11B1 promoter in CPA is significantly hypomethylated compared to 
those in AUAT and ZF. Furthermore, the experiments using H295R cells demonstrated that DNA methylation 
negatively regulated CYP11B1 promoter activity. These results demonstrated that DNA methylation is involved 
Figure 3. PRKACA or GNAS mutations induce hypomethylation of the CYP11B1 promoter in cortisol-
producing adenomas. Methylation levels were compared between cortisol-producing adenoma with (+) and 
without (−) mutations at all five CpG sites (a), two CpG sites around the Ad1/CRE binding site (b, upper panel) 
and the other three CpG sites (b, lower panel). Data are shown as the mean ± SEM (n = 8 for with mutations, 
n = 5 for without mutations), and analyzed with the Mann-Whitney U test. *P < 0.05. NS, not significant.
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in the regulation of CYP11B1 expression, and plays an important role in CYP11B1 overexpression in CPA. To 
our knowledge, this is the first study showing that DNA methylation of the CYP11B1 promoter is associated with 
cortisol overproduction in CPA.
In DNA methylation analysis, we compared the methylation status of CYP11B1 among CPA, AUAT, WBC, ZF, 
NFT, and H295R cells. Although CYP11B1 is not expressed in WBC, we performed this comparison because epi-
genetic changes could be mediated by various stimuli, thus making it important to demonstrate the methylation 
change observed in CPA (hypomethylation of CYP11B1) was not nonspecific6, 13. We also used H295R cells as a 
control because this cell line has the ability to produce mainly not cortisol but adrenal androgens under normal 
conditions.
DNA methylation regulates gene expression by blocking the binding of transcription factors to DNA13. When 
a cytosine residue is methylated at a CpG site, methyl-CpG-binding domain proteins that promote the formation 
of transcriptionally inactive forms of chromatin are recruited5. Transcription factors mainly bind to promoter 
regions. Recent studies have reported that the CYP11B2 promoter in APA is hypomethylated, suggesting that the 
hypomethylated state is associated with aldosterone overproduction7–9. To clarify the relationship between DNA 
methylation and the promoter activity, we performed experiments using H295R cells.
CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone synthase) are highly homologous genes10 and have 
three kinds of transcription factor-binding sites in their promoter regions: Ad1/CRE, Ad5, and Ad4/SF-114. The 
Ad1/CRE site has been shown to play a critical role in the transcription of CYP11B1 and is recognized by CREB, 
activating transfactor-1 (ATF-1) and ATF-215. Furthermore, a recent report demonstrated that the Ad5 and Ad4/
SF-1 sites, which are binding sites for estrogen-related receptor-α and SF-1 respectively, also play a role in the 
Figure 4. DNA methylation suppresses CYP11B1 promoter activity. (a) Confirmation of CYP11B1 promoter 
activity. H295R cells were transiently transfected with pGL4.10[luc2] (control) or pGL4-cyp11b1[−302/+7]
(CYP11B1(−302/+7)). Two days after transfection, cells were lysed and luciferase activity was measured. The 
luciferase activity of the control sample was set to 1.0, and data are shown as the mean ± SEM (n = 6), and 
analyzed with the Mann-Whitney U test. **P < 0.01. (b) Confirmation of plasmid methylation. The CYP11B1 
reporter plasmids were incubated with the CpG methyltransferase M.SssI for the indicated periods. The 
methylated plasmids were then digested by the methylation-sensitive restriction enzyme BsiEI and subjected 
to agarose electrophoresis. Note that BsiE1 cannot digest methylated plasmids. Data shown are representative 
of three independent experiments. Full-length gel is presented in Supplementary Figure S9. (c) Methylation 
suppresses CYP11B1 promoter activity. After incubation with M.SssI for the indicated periods, the CYP11B1 
reporter plasmids were transfected into H295R cells, whose lysates were subjected to luciferase assay. Luciferase 
activity of the control sample (reaction time = 0 h) was set to 100%, and the mean ± SEM (n = 4) of the data are 
shown. Data are analyzed with the Mann-Whitney U test. *P < 0.05. NS, not significant.
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regulation of CYP11B1 expression14. In the present study, we identified five CpG sites in the CYP11B1 promoter, 
all of which were present near transcription factor-binding sites. DNA methylation in the CYP11B1 promoter 
reduced its activity. We therefore conclude that DNA methylation interferes with the binding of transcription 
factors to the CYP11B1 promoter.
Recent genetic analysis identified a mutation in the PRKACA gene that causes CPA4. This mutation results 
in the release of PRKACA from the inhibitory R subunits, leading to the constitutive, cAMP-independent acti-
vation of PKA5. Moreover, GNAS mutations that activate PKA through a constitutive increase in intracellular 
cAMP concentrations are also frequently identified in CPA5, 16. Thus, both PRKACA and GNAS mutations lead 
to activation of the cAMP/PKA signaling pathway. Activated PKA phosphorylates CREB, and activated CREB 
binds to the Ad1/CRE site in the CYP11B1 promoter to induce CYP11B1 expression. A previous study reported 
that mutations in PRKACA and GNAS were associated with small tumors, young age at presentation, and a severe 
phenotype17. Another study also reported that patients with CPA containing PRKACA mutations had higher basal 
serum cortisol concentrations than patients without PRKACA mutations, which persisted after dexamethasone 
suppression tests15. However, in our study, the presence of somatic mutations made no difference in patients’ clin-
ical characteristics. This might be because our study contained fewer cases than previous studies.
Multiple causal genes of APA have also been newly discovered. Mutations in KCNJ518, ATP1A119, ATP2B319, 
and CACNA1D20 upregulate CYP11B2. Previous studies reported that there was no correlation between somatic 
mutations and DNA methylation in APA6, 8. However, in the case of CPA carrying PRKACA or GNAS mutations 
CYP11B1 promoters are significantly hypomethylated compared to wild-type CPA. More interestingly, PRKACA 
or GNAS mutations reduced DNA methylation at the two CpG sites around the Ad1/CRE binding site signifi-
cantly, but not at the other three CpG sites. Since these mutations result in the continuous PKA activation, to 
mimick the effect of these mutations, we treated H295R cells with dbcAMP, which activates PKA constitutively. 
Similarly, we observed that short-term stimulation with dbcAMP also led to the demethylation of these two CpG 
sites, but not the other CpG sites in the promoter. These data suggest that mutations in PRKACA or GNAS have 
an impact on the methylation status of the CYP11B1 promoter region, especially around the Ad1/CRE site. Since 
several studies have demonstrated that the binding of transcription factors affects DNA methylation status21–23, 
Figure 5. Activation of cAMP signaling results in hypomethylation of the CYP11B1 promoter. (a) dbcAMP 
stimulation increases CYP11B1 expression. H295R cells were stimulated with 125 µmol/L dbcAMP for three 
days, and then the expression level of CYP11B1 was examined with real-time RT-PCR analysis. The value of 
no stimulation (None) was set to 1.0, and data are shown as the mean ± SEM (n = 6) and analyzed with the 
Mann-Whitney U test. **P < 0.01. (b) dbcAMP treatment reduces methylation in the CYP11B1 promoter. 
After stimulation with dbcAMP, methylation levels at all five CpG sites (upper panel) and two CpG sites around 
the Ad1/CRE binding site (lower panel) in the CYP11B1 promoter were measured by pyrosequencing. In both 
experiments, data are shown as the mean ± SEM (n = 3), and analyzed with the Mann-Whitney U test. NS, not 
significant. *P < 0.05.
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these results suggest that somatic mutations commonly found in CPA that facilitate the binding of activated 
CREB to the Ad1/CRE site should influence DNA methylation of the CYP11B1 promoter.
In this study, we used H295R cells to examine the effect of dbcAMP on CYP11B1 expression. This cell line is 
derived from adrenal cancer and has the ability to produce adrenal androgens, but not cortisol. To correspond 
with this, the CYP11B1 promoter in H295R cells is more methylated than those in CPA and AUAT. Thus, our 
results regarding dbcAMP-stimulated hypomethylation in H295R cells might not reflect the effect of dbcAMP on 
CPA. The establishment of cortisol-producing cell line or primary culture from adrenal cortex would clarify the 
effect of dbcAMP on CPA in future.
DNA methylation might be important to not only disease states, but also to the normal physiological status of 
the adrenal glands. The adrenal cortex forms a laminar structure24 where cortisol is produced by ZF in the middle 
layer of the adrenal cortex, whereas the zona glomerulosa in the outer layer produces aldosterone. Our methylation 
analysis revealed that in CPA, the CYP11B1 promoter is significantly hypomethylated, as is CYP11B2 in APA7–9. 
These observations suggest that expression of both CYP11B1 and CYP11B2 are regulated by DNA methylation in 
adrenocortical adenomas. This raises the possibility that hypomethylation at the promoter regions of CYP11B1 
and CYP11B2 might be associated with the production of cortisol in ZF and aldosterone in the zona glomerulosa. 
In this study, we used the samples from normal adrenal cortex with non-CPA patients in order to examine the 
methylation status of normal ZF. This is because AUAT with CPA patients had atrophied due to exposure to excess 
cortisol, and we could not identify the obvious remaining ZF (Figure S3). Our results indicated that the CYP11B1 
promoter in normal ZF was significantly more hypomethylated than that in WBC or H295R cells. However, there 
was no difference in methylation status between ZF and NFT. Then, there may be the difference by the molecular 
mechanism unlike DNA methylation among both. It would be interesting to evaluate the methylation levels of the 
CYP11B1 and CYP11B2 promoters in each layer of the adrenal cortex samples in future studies.
In summary, DNA demethylation at the promoter region of the CYP11B1 gene plays an important role in 
the production of excess cortisol in CPA. Furthermore, somatic mutations associated with CPA, which result in 
the activation of the cAMP/PKA signaling pathway, induce DNA hypomethylation at the CYP11B1 promoter. 
Methylation analysis of the promoter of key enzymes appears to play a significant role in the expression of the 
enzymes and physiological regulation of hormone biosynthesis. Therefore, DNA methylation at the promoters 
might make a significant contribution to not only the pathogenesis of hormone producing adenomas, such as 
hypercortisolemia and PA, but also the hormonal synthesis mechanism of the normal adrenal gland. Our results 
might be important for the clarification of the hormonal synthesis mechanism, and the development of better 
treatments for hypertension due to hormone excess, such as hypercortisolemia and PA.
Materials and Methods
Study Patients. We studied 13 hypercortisolemia patients with CPA diagnosed between 2011 and 2015 at 
Kanazawa University Hospital. The diagnostic criteria for hypercortisolemia was based on the Endocrine Society 
Clinical Practice Guideline2. These guidelines recommend the measurement of late-night salivary cortisol for 
the diagnosis of hypercortisolemia, but this is not available in Japan. The measurement of late-night serum cor-
tisol was used instead. We also performed 131I-adosterol scintigraphy as an additional evaluation method25. In 
all patients, cortisol levels were not suppressed (>49.7 nmol/L) after 1.0 mg dexamethasone treatment. Eleven 
patients had unsuppressed cortisol concentration at midnight and/or abnormally high urinary free cortisol. In 
two other patients, both the midnight serum cortisol test and the measurement of urinary cortisol concentra-
tion could not be performed, but 131I-adosterol scintigraphy showed unilateral uptake. All patients underwent 
a unilateral adrenalectomy and needed hydrocortisone replacement treatment temporarily after surgery. They 
discontinued the replacement from 3 to 20 months (mean 8 months). In addition, we studied 7 NFT patients 
(Table S2). NFT was defined as the adrenal tumor that cortisol-, aldosterone-, androgen-producing tumor and 
pheochromocytoma were excluded by various endocrine testing.
Immunohistochemical analysis. Immunohistochemical staining of formalin-fixed paraffin-embedded 
sections of adrenal tumors was performed using monoclonal rat anti-CYP11B1 antibody and monoclonal mouse 
anti-CYP11B2 antibody with Chem Mate ENVISION kits (DAKO, Glostrup, Denmark) as previously reported26.
Protein extraction and Western blot analysis. Protein was extracted from samples T-PER Tissue 
Protein Extraction Reagent (Thermo Fisher, Bremen, Germany). Western blot was performed a previously 
reported27. Samples were mixed with an SDS sample buffer (5 × buffer: 50 mM Tris-HCl (pH 6.8), 30% glycerol, 
10% SDS, 250 mM dithiothreitol, 10 mM EDTA, and 0.01% Coomassie Brilliant Blue R250), subjected to SDS-
10% PAGE, and transferred to a nitrocellulose membrane. The membrane was incubated with antibodies for 
anti-CYP11B1 antibodies (1:20,000 dilution)11 or GAPDH (Thermo Fisher), followed by horseradish peroxidase 
(HRP)-conjugated goat anti-mouse or anti-rabbit IgG (EMD Millipore). The blot was visualized using enhanced 
chemiluminescence reagents (PerkinElmer Life Sciences, Boston, MA) with an LAS-1000 image analyzer (Fuji 
Film, Tokyo, Japan).
Gene mutation analysis. Exons 6 and 7 of the PRKACA gene and exons 8 and 9 of the GNAS 
gene were PCR amplified using the following primers: 5′-GTTTCTGACGGCTGGACTG-3′ and 
5′-AGTCCACGGCCTTGTTGTAG-3′ for exon 6–7 of PRKACA4, 5′-ACTATGTGCCGAGCGATCA-3′ and 
5′-CAGTTGGCTTACTGGAAGTTGA-3′ for exon 8 of GNAS, and 5′-ACCCCAGTCCCTCTGGAATA-3′ 
and 5′-CCAAAGAGAGCAAAGCCAAG-3′ for exon 9 of GNAS17. Exons 3 of the CTNNB1 gene 
were PCR amplified using the following primers: 5′-GCTGATTTGATGGAGTTGGAC-3′  and 
5′-CAGGACTTGGGAGGTATCCA-3′16. Direct sequencing was performed with an ABI PRISM 310 Genetic 
Analyzer (Thermo Fisher).
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Gene database of Homo sapiens cytochrome P450 family 11 subfamily B member 1 
(CYP11B1). NCBI Reference Sequence NG_007954.1 was used in this study.
Methylation analysis by pyrosequencing. Genomic DNA was extracted from CPA, AUAT, nor-
mal ZF, and NFT flash-frozen (CPA n = 12, AUAT n = 12, normal ZF n = 4, NFT n = 4) or formalin-fixed 
paraffin-embedded tissue (CPA of Case 10, AUAT of Case 12, 3 normal ZF, and 3 NFT which could not be 
obtained as flash-frozen) using Gentra Puregene Tissue Kit (Qiagen, Hilden, Germany). We collected normal ZF 
samples from normal adrenal cortex with flash-frozen (n = 4) or formalin-fixed paraffin-embedded tissue (n = 3). 
The specimens from seven patients with NFT (n = 4), renal cell carcinoma (n = 1), and extra-adrenal paragangli-
oma (n = 2) were examined. We scraped the normal ZF area to extract DNA as previously reported28. Genomic 
DNA from WBC was extracted using Puregene Blood Core Kit (Qiagen). Genomic DNA from samples was 
treated with bisulfite and PCR amplified with primers specific for human CYP11B1 promoter regions (Table S1). 
Quantitative methylation analysis of the PCR products was performed with PyroMarkGold Q96 Reagents and the 
PyroMarkQ24 pyrosequencing system (Qiagen).
Cell culture and reagents. NCI H295R human adrenocortical cells were obtained from American Type 
Culture Collection (ATCC) and cultured in a humidified 5% CO2 incubator at 37 °C in DMEM/F12 medium 
(Sigma-Aldrich, St. Louis, MO) supplemented with 2% Ultroser G (Pall, Port Washington, NY), 1% ITS plus 
Premix (BD Biosciences, Bedford, MA), and 1% penicillin/streptomycin. DbcAMP was purchased from 
Sigma-Aldrich.
Plasmid construction and methylation. Using genomic DNA prepared from H295R cells 
as a template, a 309 bp DNA fragment spanning from −302 (relative to the transcription start site) 
to +7 of human CYP11B1 gene was amplified by polymerase chain reaction (PCR) with the fol-
lowing pr imers :  5 ′-TGGCCTAACTGGCCGGTACCCAAT TCATGCCAACTCAT TCC-3 ′  and 
5′-TATCCTCGAGGCTAGCTCCAATGCTCCCTCCACCCTG-3′. The fragment was inserted into the 
KpnI/NheI sites of a pGL4.10[luc2] vector (Promega, Madison, WI) to obtain pGL4-cyp11b1[−302/+7].
To prepare CpG-methylated plasmids, plasmid DNA was incubated with the CpG methyltransferase 
M.SssI (Thermo.Fisher.com). The degree of methylation of plasmid DNA was estimated by digestion with the 
methylation-sensitive restriction enzyme BsiEI (New England Biolabs, Hanover, MD).
Luciferase assay. H295R cells were seeded in a collagen I-coated six-well plate. Plasmids were then trans-
fected with FuGENE HD transfection reagent (Promega) according to the manufacturer’s protocol. Cells were 
lysed two days after transfection, and the luciferase activity of the lysate was measured using the Dual Luciferase 
Assay Reporter System (Promega).
Real-time reverse transcription polymerase chain reaction (RT-PCR). Total RNA was 
extracted from samples using ISOGEN II (Nippon Gene, Tokyo, Japan), and reverse transcribed into cDNA. 
Quantitative real-time PCR was then performed with the SYBR Green master mix kit (Takara, Shiga, Japan). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference gene. The primers used were 
5′-GGCAGAGGCAGAGATGCTG-3′ and 5′-TCTTGGGTTAGTGTCTCCACCTG-3′ for CYP11B1, and 
5′-GAGTCAACGGATTTGGTCGT-3′ and 5′-TTGATTTTGGAGGGATCTCG-3′ for GAPDH29.
Statistics and Ethics. Data are expressed as means ± SEM. Statistical analyses were performed using Excel 
2016 (Microsoft, Seattle, WA) with the add-in software Statcel4 (OMS, Tokyo, Japan). Values of P < 0.05 were 
considered statistically significant.
This clinical study was approved by the Ethics Committees of Kanazawa University (No 2016133). The genetic 
modification experiment was approved by the Ethics Committees of Kanazawa University (No 2012019). Written 
informed consent was obtained from all patients with CPA, and from some patients with other diseases. In addi-
tion, waiver of consent of other patients was obtained from Ethics Committees of Kanazawa University. All meth-
ods were performed in accordance with the approved guidelines and regulations.
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Table S1. Characteristics of Patients with Cortisol-Producing Adenomas
BMI, body mass index; HT, hypertension; DM, diabetes mellitus; IGT, impaired glucose tolerance; HL, hyperlipidemia;    F, serum cortisol 
concentration; DST, dexamethasone suppression test; ND, no data; WT, wild type for both PRKACA and GNAS genes. ‘(+)’ represents 
























1 44/F (-) 19.3 (+) (-) (-) 6 322 ND ND 226 19 PRKACA p.L206R
2 37/F (+) 27.1 (+) (+) (+) <5 348 93 372 361 25 PRKACA p.L206R
3 60/F (-) 22.1 (+) (-) (+) 11 436 42 119 155 24 GNAS p.R201H
4 64/M (-) 23.7 (+) (+) (-) <5 441 75 149 166 30 GNAS p.R201H
5 44/F (-) 18.4 (+) (-) (-) 17 521 36 127 279 20 GNAS p.R201H
6 58/F (-) 20.4 (+) (-) (-) <5 212 35 348 102 13 GNAS p.R201S
7 52/M (+) 32.5 (+) (-) (-) 11 480 136 530 571 27 GNAS p.R201C
8 58/F (-) 26.6 (+) (-) (-) 6 223 31 138 135 22 GNAS p.Q227R
9 61/F (-) 20.7 (+) (-) (-) <5 430 44 160 83 30 WT
10 33/F (-) 29.6 (+) (-) (-) <5 221 31 243 259 23 WT
11 55/M (-) 21.1 (-) (-) (-) 16 428 40 179 83 30 WT
12 53/F (-) 22.1 (+) (+) (-) <5 417 70 579 643 23 WT
13 65/M (-) 30.5 (+) (-) (+) 5 221 ND ND 69 45 WT
Table S2. Characteristics of Patients with Non-Functioning Adrenal Tumor
NFT, non-functioning adrenal tumor; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; IGT, impaired glucose tolerance; HL, 























14 61/F (-) 20.2 (-) (-) (-) 23 11 14 4 1 11 NFT
15 57/F (-) 21.4 (-) (-) (-) 25 15 35 2 1 32 NFT
16 40/M (-) 22.0 (-) (-) (-) 10 12 ND ND 1 28 NFT
17 24/M (-) 18.8 (-) (-) (-) 29 14 31 5 1 45 NFT
18 78/F (-) 22.4 (-) (-) (-) 8 14 37 6 1 37 NFT
19 62/M (-) 32.5 (+) (-) (+) 11 11 60 5 1 21 NFT
20 44/F (-) 19.7 (-) (-) (-) 24 6 64 2 0.2 160 NFT
Primer Sequence (5’ to 3’) 
CYP11B1 Pyro-F 1-2 TTGTAATTTTTTTATTTTGTTTGGTGTTT









Table S3. Primers used for pyrosequencing
‘F’, ‘R’ and ‘S’ indicate forward, reverse and sequence primers, respectively. The 5' 
ends of reverse primers are biotinylated.
Figure S1. Immunohistochemical analysis of CYP11B1 overexpression in all cases of cortisol-producing 
adenomas 
Formalin-fixed paraffin-embedded tissue sections were stained with Hematoxylin & Eosin (HE) (left), anti-
CYP11B1 (middle), and anti-CYP11B2 antibodies (right). CPA, cortisol-producing adenoma; AUAT, 





























Figure S2. Two cortisol-producing adenomas with atypical CYP11B1 staining patterns (case 10)  






Figure S3. Immunohistochemical analysis of CYP11B1 expression in cortisol-producing adenomas and adjacent 
unaffected adrenal tissue
Formalin-fixed paraffin-embedded tissue sections were stained with anti-CYP11B1. CYP11B1 expression in 
CPAs was higher than AUATs in both cases.
CPA, cortisol-producing adenoma; AUAT, adjacent unaffected adrenal tissue.
Figure S4. Expression of CYP11B1 protein in cortisol-producing adenoma
a, Western blot analysis of tissue homogenates (20 µg of protein) by using anti-CYP11B1 and anti-GAPDH antibodies. 
Full-length blots are shown in Figure S4c. 
AUAT,  adjacent unaffected adrenal tissue  ; CPA, cortisol-producing adenoma.
b, The density of each band was measured by LAS-1000 image analyzer, and data were normalized to GAPDH. The x-
axis represents the tissue sample category: CPA (n = 5) and  AUAT (n = 5). The mean of AUAT was set to 1.0. Significant 






















































Figure S4. Expression of CYP11B1 protein in cortisol-producing adenoma






















































































































































Tumor White Blood Cell
TCGCTGCCGTGTCCT
GGTGGCCAGCGCGAT
Figure S5. Gene mutation analysis of PRKACA and GNAS gene
Figure S6. Oligonucleotide sequence of the DNA fragment spanning -302 (relative to the transcription start site) to 
+7 of the human CYP11B1 gene
Transcription factor-binding sites are indicated with underlines, and each open square represents one CpG site. 






















































Figure S7. Effect of methylation on luciferase activity of reporter plasmids
Both pGL4.10[luc2](control) and pGL4-cyp11b1[-302/+7](CYP11B1[-302/+7]) were incubated with the CpG methyltransferase M.SssI for 
the indicated period and subject to Luciferase assay.  Note here that although the luciferase activity of the control plasmid was reduced by 
methylation, the effect of methylation was smaller when compared with pGL4-cyp11b1[-302/+7]. Luciferase activity of the unmethylated 
CYP11B1[-302/+7]) sample (reaction time = 0 h) was set to 100%, and the mean ± SEM (n = 4) of the data are shown. 
Figure S8. Effect of dbcAMP treatment on DNA methylation at CpG#3-5 of the CYP11B1 promoter 
After stimulation with dbcAMP, methylation levels at 3 CpG sites (#3 - #5) in the CYP11B1
promoter was measured by pyrosequencing. 

























Figure S9. Confirmation of plasmid methylation
Full-length gel of Figure 4b is shown.
DNA 
marker
Reaction time (hr) 0 0.25 0.5 1 2 4
